Physician profile
Justin L Ellerman
NPI 1447697743
$2,932.42
in general payments reported to CMS, 2019-2025
27 companies · $626 in 2025
The $626 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $387 · 2020: $96.50 · 2021: $791 · 2022: $910 · 2024: $123 · 2025: $626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $748.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,402.52 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $191.45 | 2020-2025 | Tezspire |
| Actelion Pharmaceuticals US, INC. | $148.02 | 2021-2025 | Uptravi, Opsynvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.73 | 2025 | Ofev, Jascayd |
| Melinta Therapeutics, LLC | $122.83 | 2024 | Rezzayo |
| Glaxosmithkline, LLC. | $122.11 | 2022 | |
| Genzyme Corporation | $117.36 | 2025 | |
| United Therapeutics Corporation | $115.58 | 2021-2025 | Tyvaso, Orenitram, Remodulin |
| Amgen INC. | $76.75 | 2019 | |
| Pfizer INC. | $70.82 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $60.21 | 2025 | Dupixent |
| Bayer Healthcare Pharmaceuticals INC. | $45.60 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $44.18 | 2021-2022 | |
| Astellas Pharma US INC | $41.85 | 2022 | |
| Viatris Specialty LLC | $31.21 | 2025 | Yupelri |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $26.93 | 2019-2021 | |
| Liquidia Technologies, INC. | $22.96 | 2025 | Yutrepia |
| Mylan Specialty L.P. | $20.26 | 2019 | |
| Verona Pharma, INC. | $19.50 | 2025 | Ohtuvayre |
| Sandoz INC. | $17.17 | 2022 | |
| Merck Sharp & Dohme LLC | $16.66 | 2025 | Pifeltro |
| Novo Nordisk INC | $16.11 | 2019 | |
| Gilead Sciences, INC. | $16.07 | 2021 | |
| Sunovion Pharmaceuticals INC. | $15.44 | 2019 | |
| Csl Behring | $15.42 | 2019 | |
| Baxter Healthcare | $14.71 | 2025 | Hillrom - Volara System |
| Clovis Oncology, INC. | $12.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Ellerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.